Apmonia Therapeutics SAS is a biotechnology company dedicated to developing anti-cancer immunotherapy strategies. Our innovative technological approach is to target tumors overexpressing matricellular protein thrombospondin-1 (TSP-1).
Our long-term vision is to develop personalized immunotherapy approaches combining a proprietary therapeutic peptide targeting TSP-1 (namely TAX2 peptide) and a companion diagnostic kit, which may enable patient stratification for TAX2 therapy eligibility based on the monitoring of circulating TSP-1.
Company Details
- Employees
- 18
- Founded
- -
- Address
- 2, Esplanade Roland Garros, Reims,grand Est 51100,france
- Industry
- Biotechnology
- Website
- apmonia-therapeutics.com
- Keywords
- immunologie and oncologie.
- HQ
- Reims, Grand Est
Apmonia Therapeutics Questions
Apmonia Therapeutics's website is apmonia-therapeutics.com
Apmonia Therapeutics's LinkedIn profile is https://fr.linkedin.com/company/apmonia-therapeutics
Apmonia Therapeutics has
18 employees.
View email and phone details for 18
employees at Apmonia Therapeutics.
Apmonia Therapeutics's industry is
Biotechnology
Apmonia Therapeutics's top competitors are
Brenus Pharma,
Ribonexus,
Serendip Innovations,
Jalon Therapeutics,
Orakl Oncology,
Therasonic,
Recobia Therapeutics,
Aqemia,
Lys Therapeutics,
Carthera.
Apmonia Therapeutics's categories are Biotechnology
Apmonia Therapeutics's founding year is 2019
